Sensitive and comprehensive analysis of O-glycosylation in biotherapeutics: a case study of novel erythropoiesis stimulating protein

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Tamadon MR, Beladi-Mousavi SS. Erythropoietin; a review on current knowledge and new concepts. J. Renal Inj. Prev. 2(4), 119–121 (2013).
  Medline CASGoogle Scholar
• 2 Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus. Med. Hemother. 40(5), 302–309 (2013).
  MedlineGoogle Scholar
• 3 Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392), 1255–1260 (2003).
  Medline CASGoogle Scholar
• 4 Delorme E, Lorenzini T, Giffin J et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31(41), 9871–9876 (1992).
  Medline CASGoogle Scholar
• 5 Storring PL, Tiplady RJ, Das Reg et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol. 100, 11 (1998).
  Google Scholar
• 6 Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98(13), 3626–3634 (2001).
  Medline CASGoogle Scholar
• 7 Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur. J. Haematol. 69(5-6), 265–274 (2002).
  Medline CASGoogle Scholar
• 8 Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31(4), 290–299 (2003).
  Medline CASGoogle Scholar
• 9 Butler M. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems. Cytotechnology 50(1–3), 57–76 (2006).
  Medline CASGoogle Scholar
• 10 Su D, Zhao H, Xia H. Glycosylation-modified erythropoietin with improved half-life and biological activity. Int. J. Hematol. 91(2), 238–244 (2010).
  Medline CASGoogle Scholar
• 11 Higuchi M, Oheda M, Kuboniwa H, Tomonoh K, Shimonaka Y, Ochi N. Role of sugar chains in the expression of the biological-activity of human erythropoietin. J. Biol. Chem. 267(11), 7703–7709 (1992).
  Medline CASGoogle Scholar
• 12 Yang M, Butler M. Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation. Biotechnol. Bioeng. 68(4), 370–380 (2000).
  Medline CASGoogle Scholar
• 13 Hua S, Oh MJ, Ozcan S, Seo YS, Grimm R, An HJ. Technologies for glycomic characterization of biopharmaceutical erythropoietins. Trends Anal. Chem. 68, 18–27 (2015). •• Provides an overview of current analytical tools for qualitative and quantitative analysis of erythropoietin glycosylation.
  CASGoogle Scholar
• 14 Ruhaak LR, Zauner G, Huhn C, Bruggink C, Deelder AM, Wuhrer M. Glycan labeling strategies and their use in identification and quantification. Anal. Bioanal. Chem. 397(8), 3457–3481 (2010).
  Medline CASGoogle Scholar
• 15 Kailemia MJ, Ruhaak LR, Lebrilla CB, Amster IJ. Oligosaccharide analysis by mass spectrometry: a review of recent developments. Anal. Chem. 86(1), 196–212 (2014). •• Covers developments in the application of mass spectrometry to the analysis of carbohydrates.
  Medline CASGoogle Scholar
• 16 Balaguer E, Demelbauer U, Pelzing M, Sanz-Nebot V, Barbosa J, Neususs C. Glycoform characterization of erythropoietin combining glycan and intact protein analysis by capillary electrophoresis – electrospray – time-of-flight mass spectrometry. Electrophoresis 27(13), 2638–2650 (2006).
  Medline CASGoogle Scholar
• 17 Harazono A, Hashii N, Kuribayashi R, Nakazawa S, Kawasaki N. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS. J. Pharm. Biomed. Anal. 83, 65–74 (2013).
  Medline CASGoogle Scholar
• 18 Thaysen-Andersen M, Packer NH. Advances in LC–MS/MS-based glycoproteomics: getting closer to system-wide site-specific mapping of the N- and O-glycoproteome. Biochim. Biophys. Acta 1844(9), 1437–1452 (2014).
  Medline CASGoogle Scholar
• 19 Novotny MV, Alley WR Jr, Mann BF. Analytical glycobiology at high sensitivity: current approaches and directions. Glycoconj. J. 30(2), 89–117 (2013). • Summarizes the analytical advances made during the last several years in the structural and quantitative determinations of glycoproteins in complex biological mixtures.
  Medline CASGoogle Scholar
• 20 Alley WR Jr, Novotny MV. Structural glycomic analyses at high sensitivity: a decade of progress. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 6, 237–265 (2013). • Summarizes recent methodological developments and technical innovations toward structural characterization of glycans and their quantification at high sensitivity.
  Medline CASGoogle Scholar
• 21 Zauner G, Kozak RP, Gardner RA, Fernandes DL, Deelder AM, Wuhrer M. Protein O-glycosylation analysis. Biol. Chem. 393(8), 687–708 (2012). • Provides an overview on the methods available for analysis of O-glycosylation.
  Medline CASGoogle Scholar
• 22 Levery SB, Steentoft C, Halim A, Narimatsu Y, Clausen H, Vakhrushev SY. Advances in mass spectrometry driven O-glycoproteomics. Biochim. Biophys. Acta 1850(1), 33–42 (2015).
  Medline CASGoogle Scholar
• 23 Miura Y, Kato K, Takegawa Y et al. Glycoblotting-assisted O-glycomics: ammonium carbamate allows for highly efficient O-glycan release from glycoproteins. Anal. Chem. 82, 9 (2010).
  Google Scholar
• 24 Kozak RP, Royle L, Gardner RA, Bondt A, Fernandes DL, Wuhrer M. Improved nonreductive O-glycan release by hydrazinolysis with ethylenediaminetetraacetic acid addition. Anal. Biochem. 453, 29–37 (2014).
  Medline CASGoogle Scholar
• 25 Wang CJ, Fan WC, Zhang P, Wang ZF, Huang LJ. One-pot nonreductive O-glycan release and labeling with 1-phenyl-3-methyl-5-pyrazolone followed by ESI-MS analysis. Proteomics 11(21), 4229–4242 (2011).
  MedlineGoogle Scholar
• 26 Chittela S, Reddy TR, Krishna PR, Kashyap S. “One-pot” access to alpha-D-mannopyranosides from glycals employing ruthenium catalysis. RSC Adv. 4(86), 46327–46331 (2014).
  CASGoogle Scholar
• 27 Wang CJ, Yuan JB, Wang ZF, Huang LJ. Separation of one-pot procedure released O-glycans as 1-phenyl-3-methyl-5-pyrazolone derivatives by hydrophilic interaction and reversed-phase liquid chromatography followed by identification using electrospray mass spectrometry and tandem mass spectrometry. J. Chromatogr. A 1274, 107–117 (2013).
  Medline CASGoogle Scholar
• 28 Yang S, Hu Y, Sokoll L, Zhang H. Simultaneous quantification of N- and O-glycans using a solid-phase method. Nat. Protocols 12(6), 1229–1244 (2017).
  Medline CASGoogle Scholar
• 29 Palaniappan KK, Bertozzi CR. Chemical Glycoproteomics. Chem. Rev. 116(23), 14277–14306 (2016). •• Provides a foundation on which continued technological advancements can be made to promote further explorations of protein glycosylation.
  Medline CASGoogle Scholar
• 30 Seo Y, Kim U, Oh MJ, Yun NY, An HJ. MS platform for erythropoietin glycome characterization. Mass Spectrom. Lett. 6(3), 53–58 (2015).
  CASGoogle Scholar
• 31 An HJ, Froehlich JW, Lebrilla CB. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr. Opin. Chem. Biol. 13(4), 421–426 (2009).
  Medline CASGoogle Scholar
• 32 Ozcan S, An HJ, Vieira AC et al. Characterization of novel O-glycans isolated from tear and saliva of ocular rosacea patients. J. Proteome Res. 12(3), 1090–1100 (2013).
  Medline CASGoogle Scholar
• 33 Oh MJ, Hua S, Kim BJ et al. Analytical platform for glycomic characterization of recombinant erythropoietin biotherapeutics and biosimilars by MS. Bioanalysis 5(5), 545–559 (2013).
  CASGoogle Scholar
• 34 Hua S, Nwosu CC, Strum JS et al. Site-specific protein glycosylation analysis with glycan isomer differentiation. Anal. Bioanal. Chem. 403(5), 1291–1302 (2012).
  Medline CASGoogle Scholar
• 35 Hua S, Hu CY, Kim BJ et al. Glyco-analytical multispecific proteolysis (Glyco-AMP): a simple method for detailed and quantitative glycoproteomic characterization. J. Proteome Res. 12(10), 4414–4423 (2013).
  Medline CASGoogle Scholar
• 36 Strum JS, Nwosu CC, Hua S et al. Automated assignments of N- and O-site specific glycosylation with extensive glycan heterogeneity of glycoprotein mixtures. Anal. Chem. 85(12), 5666–5675 (2013).
  Medline CASGoogle Scholar
• 37 Kronewitter SR, An HJ, de Leoz ML, Lebrilla CB, Miyamoto S, Leiserowitz GS. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics 9(11), 2986–2994 (2009).
  Medline CASGoogle Scholar
• 38 Windwarder M, Yelland T, Djordjevic S, Altmann F. Detailed characterization of the O-linked glycosylation of the neuropilin-1 c/MAM-domain. Glycoconj. J. 33(3), 387–397 (2016).
  Medline CASGoogle Scholar
• 39 Nwosu CC, Seipert RR, Strum JS et al. Simultaneous and extensive site-specific N- and O-glycosylation analysis in protein mixtures. J. Proteome Res. 10(5), 2612–2624 (2011).
  Medline CASGoogle Scholar
• 40 Chander KB, Brnakova Z, Sanda M et al. Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4. J. Proteome Res. 13(7), 3314–3329 (2014).
  MedlineGoogle Scholar
• 41 Hashii N, Harazono A, Kuribayashi R, Takakura D, Kawasaki N. Characterization of N-glycan heterogeneities of erythropoietin products by liquid chromatography/mass spectrometry and multivariate analysis. Rapid Commun. Mass Spectrom. 28(8), 921–932 (2014).
  Medline CASGoogle Scholar
• 42 Hoefkens J, Ceroni A, Haberl P, Taylor A. Mass spectrometry in characterising biopharmaceuticals. Chim. Ogi. 32, 4–7 (2014).
  CASGoogle Scholar
• 43 Lingg N, Zhang PQ, Song ZW, Bardor M. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis. Biotechnol. J. 7(12), 1462–1472 (2012).
  Medline CASGoogle Scholar